Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Stefan Eichmüller

Head

German Cancer Research Center (DKFZ)

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

About

Stefan Eichmüller is the Head at the German Cancer Research Center (DKFZ) in Germany. His research primarily focuses on tumor immunology, including T cell therapies, neoantigen detection, and the role of microRNAs in cancer susceptibility. Recent articles highlight his work on peptide-receptive MHC class I multimers and the therapeutic potential of carbon ion irradiation combined with immunotherapy. Dr. Eichmüller is also investigating the mechanisms of antigen presentation and its implications for hematopoietic stem cell integrity.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (3)

Marten Meyer

Deputy Head

German Cancer Research Center

GERMANY

View details

Angelika Riemer

Division Head

Deutsches Krebsforschungszentrum

GERMANY

View details

Barbara Seliger

Martin Luther University Halle-Wittenberg

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stefan Eichmüller

Research Interests

Explore related searches

About

Articles (10)

MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.

MicroRNAs affecting the susceptibility of melanoma cells to CD8+ T cell‐mediated cytolysis

Novel microRNAs modulating ecto-5'-nucleotidase expression.

IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.

Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.

SOX9 is a target of miR-134-3p and miR-224-3p in breast cancer cell lines.

Antigen presentation safeguards the integrity of the hematopoietic stem cell pool.

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.

Reply to: Comments on “Cost of decentralized CAR T cell production in an academic non‐profit setting”

Cost of decentralized CAR T‐cell production in an academic nonprofit setting

Collaborators (3)

Marten Meyer

Angelika Riemer

Barbara Seliger

Make your next move.